Meeting
2015 Genitourinary Cancers Symposium
Institutional retrospective review of presurgical cisplatin-based chemotherapy (chemo) in patients with urothelial carcinoma (UC): Gemcitabine+cisplatin (GC) versus dose-dense methotrexate, vinblastine, doxorubicin, cisplatin (ddMVAC).
Authors
Lauren Christine Harshman
Dana-Farber Cancer Institute, Boston, MA
Lauren Christine Harshman , Susanna J. Jacobus , Stephanie A. Mullane , Hope Feldman , Michelle S. Hirsch , Philip W. Kantoff , Toni K. Choueiri , Joaquim Bellmunt
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Prostate, Penile, Testicular, and Urethral Cancers, and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Urothelial Carcinoma
Citation
J Clin Oncol 33, 2015 (suppl 7; abstr 365)
DOI
10.1200/jco.2015.33.7_suppl.365
Abstract #
365
Poster Bd #
H2
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
FDG PET-CT imaging in assessing interim response to neoadjuvant cisplatin-based chemotherapy (NAC) in muscle invasive bladder cancer (MIBC): A prospective study.
First Author: Srikala S. Sridhar
Poster
2019 Genitourinary Cancers Symposium
Comparing clinical outcomes between patients with urothelial carcinoma who treated neoadjuvant chemotherapy by gemcitabine-cisplatin and dose-dense MVAC.
First Author: Yongjune Lee
Poster
2014 ASCO Annual Meeting
Comparative effectiveness of gemcitabine plus cisplatin (GC) versus methotrexate, vinblastine, doxorubicin, plus cisplatin (MVAC) as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC).
First Author: Matt D. Galsky
Poster
2020 Genitourinary Cancers Symposium
Resource utilization analysis of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (DD-MVAC) versus gemcitabine-cisplatin (GC) as neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC).
First Author: Kamaneh Montazeri